| Assessment Status | Rapid Review complete |
| HTA ID | 24011 |
| Drug | Enalapril maleate |
| Brand | Aqumeldi® |
| Indication | For the treatment of heart failure in children and adolescents from birth to less than 18 years of age. |
| Assessment Process | |
| Rapid review commissioned | 25/03/2024 |
| Rapid review completed | 12/04/2024 |
| Rapid review outcome | A full HTA is not recommended. The NCPE recommends that enalapril maleate mini ODTs not be considered for reimbursement at the submitted price.* |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
The HSE has approved reimbursement. October 2025